Information Provided By:
Fly News Breaks for March 8, 2018
BIIB, ABBV
Mar 8, 2018 | 05:42 EDT
After hosting a meeting with investors at AbbVie's (ABBV) headquarters this week, Piper Jaffray analyst Christopher Raymond believes the shares can "continue to work." The analyst believes the stock can continue outperforming on "solid" commercial and clinical performance. Management expressed no urgency for a larger commercial or late-stage acquisition, Raymond tells investors in a research note. The analyst says he's glad he never wrote that AbbVie for Biogen (BIIB) research note. He keeps an Overweight rating on AbbVie.